JP2025510678A5 - - Google Patents
Info
- Publication number
- JP2025510678A5 JP2025510678A5 JP2024555897A JP2024555897A JP2025510678A5 JP 2025510678 A5 JP2025510678 A5 JP 2025510678A5 JP 2024555897 A JP2024555897 A JP 2024555897A JP 2024555897 A JP2024555897 A JP 2024555897A JP 2025510678 A5 JP2025510678 A5 JP 2025510678A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody conjugate
- conjugate according
- pharmaceutically acceptable
- antibody
- fuc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22163928 | 2022-03-23 | ||
| EP22163928.9 | 2022-03-23 | ||
| PCT/EP2023/057565 WO2023180489A1 (en) | 2022-03-23 | 2023-03-23 | Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510678A JP2025510678A (ja) | 2025-04-15 |
| JP2025510678A5 true JP2025510678A5 (https=) | 2026-04-01 |
Family
ID=80930396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024555897A Pending JP2025510678A (ja) | 2022-03-23 | 2023-03-23 | カルシノエンビロニック抗原を発現する腫瘍を標的化するための抗体コンジュゲート |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250082770A1 (https=) |
| EP (1) | EP4496595A1 (https=) |
| JP (1) | JP2025510678A (https=) |
| KR (1) | KR20250024741A (https=) |
| CN (1) | CN119233830A (https=) |
| AU (1) | AU2023237620A1 (https=) |
| CA (1) | CA3254964A1 (https=) |
| IL (1) | IL315205A (https=) |
| MX (1) | MX2024011519A (https=) |
| WO (1) | WO2023180489A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113260384A (zh) | 2018-11-05 | 2021-08-13 | 西纳福克斯股份有限公司 | 用于靶向表达trop-2的肿瘤的抗体缀合物 |
| IL315366A (en) | 2022-03-23 | 2024-11-01 | Synaffix Bv | Antibody pairs for targeting PTK7-expressing tumors |
| EP4737483A1 (en) * | 2023-06-30 | 2026-05-06 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate production method including purification step using activated carbon material |
| WO2025238253A1 (en) * | 2024-05-16 | 2025-11-20 | Synaffix B.V. | Antibody-oligonucleotide conjugates |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4939255A (en) | 1987-06-24 | 1990-07-03 | Daiichi Pharmaceutical Co., Ltd. | Hexa-cyclic camptothecin derivatives |
| US5872215A (en) | 1991-12-02 | 1999-02-16 | Medical Research Council | Specific binding members, materials and methods |
| GB9317423D0 (en) | 1993-08-21 | 1993-10-06 | Imp Cancer Res Tech | Monoclonal antibodies |
| GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
| US5874540A (en) * | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| GB9621295D0 (en) | 1995-12-07 | 1996-11-27 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| US7232888B2 (en) | 2002-07-01 | 2007-06-19 | Massachusetts Institute Of Technology | Antibodies against tumor surface antigens |
| CN101972478B (zh) | 2002-10-08 | 2012-10-31 | 免疫医疗公司 | 抗体治疗 |
| US7273608B2 (en) | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
| JP5399712B2 (ja) | 2005-12-21 | 2014-01-29 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 可溶性ｃｅａに対する抵抗性を有する医薬組成物 |
| DK3438131T3 (da) | 2006-02-10 | 2022-04-11 | Life Technologies Corp | Oligosaccharidmodifikation og mærkning af proteiner |
| WO2009102820A2 (en) | 2008-02-11 | 2009-08-20 | Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services | Modified sugar substrates and methods of use |
| KR101528013B1 (ko) | 2009-08-31 | 2015-06-16 | 로슈 글리카트 아게 | 친화성-성숙된 인간화된 항-ｃｅａ 단일클론 항체 |
| PL2621955T3 (pl) | 2010-10-01 | 2018-07-31 | National Research Council Of Canada | Przeciwciała anty-CEACAM6 i ich zastosowania |
| PE20141017A1 (es) | 2011-03-02 | 2014-08-25 | Roche Glycart Ag | Anticuerpos del cea |
| CN105142672B (zh) | 2012-10-23 | 2019-04-05 | 西纳福克斯股份有限公司 | 经修饰的抗体、抗体-缀合物及其制备方法 |
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| CN110627797A (zh) * | 2012-12-21 | 2019-12-31 | 麦迪穆有限责任公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| CA2924398A1 (en) | 2013-11-05 | 2015-05-14 | Immunomedics, Inc. | Humanized anti-ceacam5 antibody and uses thereof |
| EP4148138A1 (en) | 2014-08-04 | 2023-03-15 | SynAffix B.V. | Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof |
| CN107106701B (zh) | 2014-10-03 | 2020-11-06 | 西纳福克斯股份有限公司 | 磺酰胺接头、其缀合物及制备方法 |
| PE20171790A1 (es) | 2015-03-23 | 2017-12-28 | Bayer Pharma AG | Anticuerpos anti-ceacam6 y sus usos |
| WO2016170186A1 (en) | 2015-04-23 | 2016-10-27 | Synaffix B.V. | PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A β(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE |
| WO2017137458A1 (en) * | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates |
| WO2017137457A1 (en) * | 2016-02-08 | 2017-08-17 | Synaffix B.V. | Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates |
| EP3413920A1 (en) * | 2016-02-08 | 2018-12-19 | Synaffix B.V. | Bioconjugates containing sulfamide linkers for use in treatment |
| CA3026651A1 (en) | 2016-06-09 | 2017-12-14 | Blinkbio, Inc. | Silanol based therapeutic payloads |
| EP3720504A1 (en) | 2017-12-06 | 2020-10-14 | Synaffix B.V. | Enediyne conjugates |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| MX2021011812A (es) | 2019-03-29 | 2021-10-22 | Medimmune Ltd | Compuestos y conjugados de estos. |
| SG11202110922QA (en) | 2019-04-26 | 2021-10-28 | Immunogen Inc | Camptothecin derivatives |
| WO2021053587A1 (en) | 2019-09-18 | 2021-03-25 | Klaus Strein | Bispecific antibodies against ceacam5 and cd3 |
| KR20230021018A (ko) | 2020-06-05 | 2023-02-13 | 재단법인 생물기술개발중심 | 항-메조텔린 항체를 함유하는 항체-약물 컨쥬게이트 및 이의 용도 |
| NL2026947B1 (en) | 2020-11-20 | 2022-07-01 | Synaffix Bv | Tyrosine-based antibody conjugates |
| CN113816969B (zh) | 2021-04-30 | 2024-01-16 | 联宁（苏州）生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
| KR20230015301A (ko) | 2021-07-19 | 2023-01-31 | 맙플렉스 인터내셔널 컴퍼니 리미티드 | 2성분 독소가 부하된 항체-약물 접합체 및 그의 용도 |
-
2023
- 2023-03-23 KR KR1020247034723A patent/KR20250024741A/ko active Pending
- 2023-03-23 AU AU2023237620A patent/AU2023237620A1/en active Pending
- 2023-03-23 JP JP2024555897A patent/JP2025510678A/ja active Pending
- 2023-03-23 WO PCT/EP2023/057565 patent/WO2023180489A1/en not_active Ceased
- 2023-03-23 CA CA3254964A patent/CA3254964A1/en active Pending
- 2023-03-23 EP EP23715080.0A patent/EP4496595A1/en active Pending
- 2023-03-23 IL IL315205A patent/IL315205A/en unknown
- 2023-03-23 MX MX2024011519A patent/MX2024011519A/es unknown
- 2023-03-23 CN CN202380028865.6A patent/CN119233830A/zh active Pending
-
2024
- 2024-09-20 US US18/892,256 patent/US20250082770A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025510678A5 (https=) | ||
| JP2025510623A5 (https=) | ||
| EP0180564B1 (en) | Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines and reagents | |
| US5391723A (en) | Oligonucleotide conjugates | |
| JP2023534131A5 (https=) | ||
| JP2023166395A5 (https=) | ||
| Jennings et al. | Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. | |
| JP5933923B2 (ja) | 新規な複合タンパク質及びペプチド | |
| JP2024028453A5 (https=) | ||
| JP2024010112A5 (https=) | ||
| JP2002513028A (ja) | ポリサッカリド抗原結合体 | |
| JP2022541517A5 (https=) | ||
| JP2020189977A5 (https=) | ||
| JP2021517113A5 (https=) | ||
| JP2001506990A (ja) | 一価の（ｍｏｎｏｖａｌｅｎｔ）抗体フラグメント | |
| IE58088B1 (en) | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency | |
| JP2004501869A (ja) | ヒドラジンベース及びカルボニルベースの二官能性架橋剤 | |
| JP2001512438A (ja) | αガラクトシルエピトープで標識された抗体による免疫応答の刺激 | |
| FR2581877A1 (fr) | Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries | |
| JP2009501127A5 (https=) | ||
| CN106706894B (zh) | 一种基于间接竞争酶联免疫法定量检测油胺枝接聚琥珀酰亚胺高分子纳米药物载体的方法 | |
| JPH0343280B2 (https=) | ||
| JP2006514627A5 (https=) | ||
| JP2002504096A (ja) | タンパク質−多糖ワクチンの調製のための未修飾タンパク質とハロアシルまたはジハロアシル誘導体化された多糖との結合 | |
| JP2005530493A5 (https=) |